Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get trading ideas, historical data, advanced options screeners, more. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Ngm Biopharmaceuticals Inc (NGM)

Ngm Biopharmaceuticals Inc (NGM)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 451,945
  • Shares Outstanding, K 81,726
  • Annual Sales, $ 77,880 K
  • Annual Income, $ -120,340 K
  • 60-Month Beta 1.22
  • Price/Sales 5.88
  • Price/Cash Flow N/A
  • Price/Book 1.57
Trade NGM with:

Options Overview Details

View History
  • Implied Volatility 78.39% ( -5.16%)
  • Historical Volatility 75.08%
  • IV Percentile 8%
  • IV Rank 7.99%
  • IV High 325.02% on 10/11/22
  • IV Low 56.98% on 11/11/22
  • Put/Call Vol Ratio 0.00
  • Today's Volume 2
  • Volume Avg (30-Day) 35
  • Put/Call OI Ratio 0.15
  • Today's Open Interest 3,985
  • Open Int (30-Day) 9,448

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate -0.52
  • Number of Estimates 5
  • High Estimate -0.47
  • Low Estimate -0.57
  • Prior Year -0.35
  • Growth Rate Est. (year over year) -48.57%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.97 +12.68%
on 11/22/22
6.14 -8.79%
on 11/15/22
+0.02 (+0.36%)
since 11/07/22
3-Month
2.92 +91.78%
on 10/17/22
16.49 -66.04%
on 09/09/22
-10.20 (-64.56%)
since 09/07/22
52-Week
2.92 +91.78%
on 10/17/22
19.14 -70.74%
on 01/04/22
-12.55 (-69.15%)
since 12/07/21

Most Recent Stories

More News
How Much Upside is Left in NGM Biopharmaceuticals (NGM)? Wall Street Analysts Think 462%

The mean of analysts' price targets for NGM Biopharmaceuticals (NGM) points to a 461.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement...

NGM : 5.60 (+1.27%)
NGM Biopharmaceuticals (NGM) Reports Q3 Loss, Tops Revenue Estimates

NGM Biopharmaceuticals (NGM) delivered earnings and revenue surprises of 3.28% and 12.66%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?...

NGM : 5.60 (+1.27%)
TWST : 25.32 (-2.20%)
NGM Biopharmaceuticals: Q3 Earnings Snapshot

NGM Biopharmaceuticals: Q3 Earnings Snapshot

NGM : 5.60 (+1.27%)
After Plunging 59.4% in 4 Weeks, Here's Why the Trend Might Reverse for NGM Biopharmaceuticals (NGM)

The heavy selling pressure might have exhausted for NGM Biopharmaceuticals (NGM) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street...

NGM : 5.60 (+1.27%)
Cara Therapeutics (CARA) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Cara (CARA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CARA : 12.43 (+0.89%)
NGM : 5.60 (+1.27%)
After Plunging 76.6% in 4 Weeks, Here's Why the Trend Might Reverse for NGM Biopharmaceuticals (NGM)

NGM Biopharmaceuticals (NGM) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings...

NGM : 5.60 (+1.27%)
Bank of America, BP rise; Fox, NGM Biopharmaceuticals fall

NEW YORK (AP) — Stocks that traded heavily or had substantial price changes Monday:

GDOT : 18.34 (-1.40%)
GS : 359.92 (-0.82%)
FOXA : 30.70 (-0.97%)
CLR : 74.27 (+0.04%)
BAC : 32.74 (-0.79%)
BP : 33.91 (-1.34%)
NGM : 5.60 (+1.27%)
CS : 3.17 (-1.55%)
NGM Biopharmaceuticals (NGM) Reports Q2 Loss, Misses Revenue Estimates

NGM Biopharmaceuticals (NGM) delivered earnings and revenue surprises of -7.27% and 37.94%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

NGM : 5.60 (+1.27%)
FBIO : 0.6600 (-0.71%)
Bluebird Bio (BLUE) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

Bluebird (BLUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BLUE : 7.94 (+1.40%)
NGM : 5.60 (+1.27%)
NGM Biopharmaceuticals (NGM) Soars 6.8%: Is Further Upside Left in the Stock?

NGM Biopharmaceuticals (NGM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price...

NGM : 5.60 (+1.27%)
DBVT : 1.2800 (-2.29%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

NGM Biopharmaceuticals Inc. is focused on developing novel therapeutics for underlying cardio-metabolic, liver, oncologic and ophthalmic diseases. The company's product pipeline consists of NGM282, NGM313, NGM120, NGM217, NGM621, NGM386 and NGM395 which are in clinical stage. NGM Biopharmaceuticals Inc....

See More

Key Turning Points

3rd Resistance Point 5.93
2nd Resistance Point 5.79
1st Resistance Point 5.70
Last Price 5.60
1st Support Level 5.47
2nd Support Level 5.33
3rd Support Level 5.24

See More

52-Week High 19.14
Fibonacci 61.8% 12.94
Fibonacci 50% 11.03
Fibonacci 38.2% 9.12
Last Price 5.60
52-Week Low 2.92

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar